Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Maciej Kujawski, … , Heidi Kay, Hua Yu
Maciej Kujawski, … , Heidi Kay, Hua Yu
Published September 5, 2008
Citation Information: J Clin Invest. 2008;118(10):3367-3377. https://doi.org/10.1172/JCI35213.
View: Text | PDF
Research Article Oncology

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

  • Text
  • PDF
Abstract

The underlying molecular mechanisms that cause immune cells, mediators of our defense system, to promote tumor invasion and angiogenesis remain incompletely understood. Constitutively activated Stat3 in tumor cells has been shown to promote tumor invasion and angiogenesis. Therefore, we sought to determine whether Stat3 activation in tumor-associated inflammatory cells has a similar function. We found that Stat3 signaling mediates multidirectional crosstalk among tumor cells, myeloid cells in the tumor stroma, and ECs that contributes to tumor angiogenesis in mice. Myeloid-derived suppressor cells and macrophages isolated from mouse tumors displayed activated Stat3 and induced angiogenesis in an in vitro tube formation assay via Stat3 induction of angiogenic factors, including VEGF and bFGF. Stat3-regulated factors produced by both tumor cells and tumor-derived myeloid cells also induced constitutive activation of Stat3 in tumor endothelium, and inhibiting Stat3 in ECs substantially reduced in vitro tumor factor–induced endothelial migration and tube formation. In vivo assays demonstrated the requirement for Stat3 signaling in tumor-associated myeloid cells for tumor angiogenesis. Our results indicate that, by virtue of the ability of Stat3 in tumor cells and tumor-derived myeloid cells to upregulate expression of factors that activate Stat3 in ECs, Stat3 mediates multidirectional crosstalk among tumor cells, tumor-associated myeloid cells, and ECs that contributes to tumor angiogenesis.

Authors

Maciej Kujawski, Marcin Kortylewski, Heehyoung Lee, Andreas Herrmann, Heidi Kay, Hua Yu

×

Figure 2

Role of Stat3 activity and different populations of myeloid cells in angiogenesis.

Options: View larger image (or click on image) Download as PowerPoint
Role of Stat3 activity and different populations of myeloid cells in ang...
(A) In vitro collagen tube formation assays using different subsets of CD11b+ myeloid cells. Both Gr1+CD11b+CD11c– cells and Gr1–CD11b+CD11c– cells in the presence of 2.5% tumor-conditioned medium successfully induced ECs to form tube-like structures. Gr1–CD11b+CD11c+ DCs did not induce efficient EC tube formation. Graph shows mean ± SEM of 2 independent experiments. (B) VEGF and bFGF expression in CD11b+Gr1+ myeloid cells contribute to angiogenesis. Splenic CD11b+Gr1+ myeloid cells were exposed to tumor-conditioned medium. Left: Flow cytometric analysis of Stat3+/+ and Stat3–/– CD11b+Gr1+ myeloid cells isolated from spleens of tumor-bearing mice for phospho-Stat3 (p-Stat3) and VEGF levels. Levels of bFGF in the indicated cells were determined by the Luminex system (see Methods). Graph shows mean ± SEM of 2 independent experiments. Right: Neutralization of VEGF and VEGF together with bFGF partially but significantly reduced myeloid cell–mediated angiogenesis. Graph shows mean ± SEM of 2 independent experiments with triplicates. (C) VEGF and bFGF are important for Stat3-dependent, tumor-derived MDSC–mediated angiogenesis. MDSCs purified from B16 tumors were used for tube formation assays in the presence of the indicated antibodies. Data are mean ± SEM of 3 independent experiments, each involving 10–15 pooled mice per group done in triplicates. (D) Stat3 activity in tumor-associated myeloid cells contributes to elevated expression of multiple angiogenic factors. Stat3+/+ and Stat3–/– CD11b+ myeloid cells were directly isolated from B16 tumors, and real-time RT-PCR was performed to detect RNA levels of the indicated genes. RNA levels of each indicated gene relative to a housekeeping gene (either 18s or GAPDH) in Stat3+/+ myeloid cells were assigned as 1. Data are mean ± SEM (n = 3). *P < 0.05; **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts